<h4>Objective</h4>This study aimed to explore the effect of prostate-specific membrane antigen (PSMA) positron emission tomography and computed tomography (PET/CT) on clinical TNM (cTNM) staging assessment and treatment decision-making in prostate cancer,providing real-world evidence for its clinical application in China.<h4>Methods</h4>We retrospectively analyzed the clinical data of 125 prostate cancer patients who underwent PSMA PET/CT at Chongqing University Cancer Hospital from January 2019 to June 2022. The gene discussed is FOLH1; the disease is Familial prostate cancer.